Please check your internet connection and try again.
# Hepamerz (l-Ornithine l-Aspartate)
## Overview
l-Ornithine l-Aspartate (LOLA) is a combination of two amino acids that is thought to reduce ammonia levels in the body. It is primarily used in the management of hyperammonemia associated with liver disease.
## Primary Indications
* Treatment of latent and manifest hepatic encephalopathy (HE) in patients with liver cirrhosis.
## Adult Dosing
* **Initial Dose:** 5-10 grams (equivalent to one sachet or vial) administered orally or intravenously every 8 hours.
* **Maintenance Dose:** 5-10 grams every 8-12 hours, as tolerated and based on clinical response.
* **Maximum Dose:** Not explicitly defined, but typically does not exceed 30 grams per day. Dosing is often guided by local protocols and patient response.
## Pediatric Dosing
* There is limited established pediatric dosing. Use is generally not recommended in children due to insufficient data. If used, it should be under strict medical supervision and based on expert clinical judgment.
## Dose Adjustments
* No specific dose adjustments are typically required for renal or hepatic impairment, as LOLA is metabolized and excreted by the liver and kidneys, respectively. However, close monitoring for efficacy and adverse effects is crucial in patients with severe organ dysfunction.
## Contraindications
* Hypersensitivity to l-Ornithine l-Aspartate or any of its components.
* Severe renal impairment (creatinine clearance < 30 mL/min), although this is sometimes debated and may depend on the specific formulation and clinical context.
## Adverse Effects
* Gastrointestinal disturbances: Nausea, vomiting, abdominal pain, diarrhea.
* Rarely: Allergic reactions.
* With intravenous administration: Phlebitis at the injection site.
## Key Drug Interactions
* No significant drug interactions have been consistently reported. However, caution is advised when co-administering with other medications affecting ammonia levels or amino acid metabolism.
## Monitoring
* Clinical signs and symptoms of hepatic encephalopathy (e.g., confusion, asterixis).
* Serum ammonia levels (though not always directly correlated with clinical improvement).
* Renal and hepatic function.
## Clinical Pearls
* LOLA works by promoting the detoxification of ammonia in the liver and extrahepatic tissues.
* Oral administration may be preferred for long-term management to avoid complications associated with intravenous access.
* The response to LOLA can vary, and it is often used as an adjunct to other therapies for HE (e.g., lactulose, antibiotics).
***
*Disclaimer: This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for definitive guidance. Dosing and recommendations may vary.*
